Rucaparib: A Promising Therapy for Ovarian and Prostate Cancer
Rucaparib is a member of a class of drugs known as PARP (Poly (ADP-ribose) polymerase) inhibitors. These inhibitors work by targeting cancer cells with defective DNA repair mechanisms, particularly those associated with BRCA1 and BRCA2 gene mutations.
